BERLncs May Aid in Clinical Decision-Making for Patients With Adenocarcinoma

Base excision repair-related long noncoding RNAs (BERLncs) may provide valuable clinical decision-making insight for clinicians who treat patients with lung adenocarcinoma.

Junzheng Zhang, PhD, and colleagues conducted a study in China in which they developed a risk score model for 19 BERLncs. Patients included in the study were divided into a high-risk cohort and a low-risk cohort. Disparities in tumor mutation burden (TMB), immune infiltration, tumor immune dysfunction and exclusion (TIDE) score, chemosensitivity, and immune checkpoint gene expression were investigated between the cohorts using comparative analyses.

The high-risk cohort was associated with significantly lower OS compared with the low-risk cohort. Moreover, high-risk patients demonstrated elevated TMB, diminished TIDE scores, and an immunosuppressive tumor microenvironment. Patients in the low-risk cohort showed potential benefits from immunotherapy.

In addition, the BERLncs risk model identified potential anticancer agents, according to study findings.

Since lung adenocarcinoma is the most common type of lung cancer, the risk model shows promise as a prognostic biomarker for patients with the disease, “providing valuable insights for clinical decision-making, therapeutic strategies, and understanding of underlying biological mechanisms,” the authors wrote.